http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ren, Zi Yan,Zhang, Dian Hai,Pham, Minh Trien,Koh, Chang Seop Trans Tech Publications, Ltd. 2012 Materials science forum Vol.721 No.-
<P>A novel reliability calculation algorithm is developed and applied to a robust optimization of electromagnetic device with uncertain design variables taken into account. The proposed algorithm, to calculate the reliability of a given design, incorporates sensitivity analysis based on finite element method with Monte Carlo simulation (MCS) method so that it has higher numerical efficiency than conventional methods: MCS and first-order reliability methods. Through numerical examples, its applicability to a reliability-based robust optimal design of electromagnetic device is demonstrated.</P>
Dou, Xue,Wang, Ren-Ben,Meng, Xiang-Jiao,Yan, Hong-Jiang,Jiang, Shu-Mei,Zhu, Kun-Li,Xu, Xiao-Qing,Chen, Dong,Song, Xian-Rang,Mu, Dian-Bin Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.2
Objective: The purpose of this study was to examine the role of programmed cell death 4 (PDCD4) expression in predicting tumor response to neoadjuvant chemoradiotherapy and outcomes for patients with locally advanced rectal cancer. Methods: Clinicopathological factors and expression of PDCD4 were evaluated in 92 patients with LARC treated with nCRT. After the completion of therapy, 4 cases achieved clinical complete response (cCR), and thus the remaining 88 patients underwent a standardized total mesorectal excision procedure. There were 38 patients (41.3%) with a good response (TRG 3-4) and 54 (58.7%) with a poor one (TRG 0-2). Results: Immunohistochemical staining analyses showed that patients with high expression of PDCD4 were more sensitive to nCRT than those with low PDCD4 expression (P=0.02). High PDCD4 expression before nCRT and good response (TRG3-4) were significantly associated with improved 5-year disease-free survival and 5-year overall survival (P<0.05). Multivariate analysis demonstrated that the pretreatment PDCD4 expression was an independent prognostic factor. Conclusion: Our study demonstrated that high expression of PDCD4 protein is a useful predictive factor for good tumor response to nCRT and good outcomes in patients with LARC.
Optimization Design and Performance Analysis of Thomson-Coil Actuator by using Different Algorithms
렌지얀(Zi Van Ren),장전해(Dian Hai Zhang),리웨이(Wei Li),고창섭(Chang Seop Koh) 대한전기학회 2010 대한전기학회 학술대회 논문집 Vol.2010 No.10
In this paper, the optimization design and performance analysis of Thomson-coil actuator are implemented by using two different algorithms: enumeration algorithm and one global mixed-variable optimization algorithm based on the particle swarm optimization algorithm. The efficiency of these two methods are compared. Finally, the best design is obtained and corresponding dynamic performances are analysed.
Dou, Xue,Wang, Ren-Ben,Yan, Hong-Jiang,Jiang, Shu-Mei,Meng, Xiang-Jiao,Zhu, Kun-Li,Xu, Xiao-Qing,Mu, Dian-Bin Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.6
Objective: The objective of this study was to identify clinical predictive factors for tumor response after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC). Methods: All factors were evaluated in 88 patients with LARC treated with nCRT. After a long period of 4-8 weeks of chemoradiotherapy, 3 patients achieved clinical complete response (cCR) and thus aggressive surgery was avoided, and the remaining 85 patients underwent a curative-intent operation. The response to nCRT was evaluated by tumor regression grade (TRG) system. Results: There were 32 patients (36.4%) with good tumor regression (TRG 3-4) and 56 (63.6%) with poor tumor regression (TRG 0-2). Lymphocyte counts and ratios were higher in good response cases (P=0.01, 0.03, respectively) while neutrophil ratios and N/L ratios were higher in poor response cases (P=0.04, 0.02, respectively). High lymphocyte ratios before nCRT and good tumor regression (TRG3-4) were significantly associated with improved 5-year disease-free survival (P<0.05). Pretreatment nodal status was also significantly associated with 5-year disease-free survival and 5-year overall survival (P<0.05). Multivariate analysis confirmed that the pretreatment lymphocyte ratio and lymph nodal status were independent prognostic factors. Conclusion: Our study suggested that LARC patients with high lymphocyte ratios before nCRT would have good tumor response and high 5-year DFS and OS.
HE4 as a Serum Biomarker for ROMA Prediction and Prognosis of Epithelial Ovarian Cancer
Chen, Wen-Ting,Gao, Xiang,Han, Xiao-Dian,Zheng, Hui,Guo, Lin,Lu, Ren-Quan Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.1
Background and Purpose: Human epididymis protein 4 (HE4) has been suggested to be a novel biomarker of epithelial ovarian cancer (EOC). The present study aimed to evaluate and compare HE4 with the commonly used marker, carbohydrate antigen 125 (CA125), in prediction and therapy-monitoring of EOC. Patients and Methods: Serum HE4 concentrations from 123 ovarian cancer patients and 174 controls were measured by Roche electrochemiluminescent immunoassay (ECLIA). Risk of ovarian malignancy algorithm (ROMA) values were calculated and assessed. In addition, the prospects of HE4 detection for therapy-monitoring were evaluated in EOC patients. Results: The ROMA score could classify patients into high- and low-risk groups with malignancy. Indeed, lower serum HE4 was significantly associated with successful surgical therapy. Specifically, 38 patients with EOC exhibited a greater decline of HE4 compared with CA125. In contrast, elevation of HE4 better predicted recurrence (of 46, 11 patients developed recurrence, and with it increased HE4 serum concentrations) and a poor prognosis than CA125. Conclusions: This study suggests that serum HE4 levels are closely associated with outcome of surgical therapy and disease prognosis in Chinese EOC patients.
Shikang Zhao,Wei Liu,Shuo Li,Tao Shi,Qiusong Chen,Qi Li,Leina Sun,Dian Ren,Zuoqing Song,Chun Huang,Song Xu 대한암학회 2021 Cancer Research and Treatment Vol.53 No.2
A 61-year-old male patient was simultaneously diagnosed with lung adenocarcinoma and inflammatory myofibroblastic tumor (IMT). The lung adenocarcinoma and IMT harbored two distinct types of ALK translocation, LOC101927285-ALK, and TPM3-ALK, respectively. The ALK Ventana showed strong positivity on both lesions. The patient was therefore given an endobronchial cryotherapy and ALK inhibitor crizotinib. The tumors showed durable response however the left lung adenocarcinoma relapsed at 17th month post-crizotinib treatment. Tissue re-biopsy on the resistant tumor revealed an ALK exon 23 C1156Y missense mutation in addition to LOC101927285-ALK mutation. Further RNA-based sequence uncovered that the noncoding region rearrangement is the fusion mutation of EML4-ALK. The patient was therefore received alectinib, and the tumor exhibited partly response. Overall, it is very rare that two types of pulmonary tumors exist in one patient driven by two distinct ALK fusions, which emphasizes the necessity of gene sequencing in clinical decision-making and individualized therapy.